EPO and myelodysplastic syndrome: Given that EPO is involved in the control of erythroid and other hematopoietic cell production, [8-11] and because MDS is characterized by impaired production of hematopoietic cells and may respond to EPO therapy, [12-14] we hypothesized that the EPO promoter SNP may show some association with MDS.